Could a diabetes drug curb heavy drinking in HIV patients?

NCT ID NCT07040592

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether semaglutide, a drug used for diabetes and weight loss, can help people with HIV reduce their alcohol use. Thirty participants will receive the drug along with support from a pharmacist and psychiatrist. The goal is to see if this approach is feasible, acceptable, and safe, and whether it leads to less drinking.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If it works, this could point toward a new way to help people with HIV reduce heavy drinking, potentially improving their overall health.
What could go wrong: This is a very small, early pilot study with only 30 participants, so results may not apply broadly. The medication is being used off-label, and side effects or lack of effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER (AUD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER (AUD) HIV

Contacts and locations

Locations

Atlanta VA Medical Center
RECRUITING

Decatur, Georgia, 30033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.